Follow
Arnoud J Templeton
Arnoud J Templeton
St. Claraspital Basel/St. Clara Research Ltd, Switzerland
Verified email at unibas.ch
Title
Cited by
Cited by
Year
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
22702014
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisPrognostic Role of PLR in Solid Tumors
AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ...
Cancer epidemiology, biomarkers & prevention 23 (7), 1204-1212, 2014
5822014
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum, AJ Templeton, ...
Lung cancer 111, 176-181, 2017
5312017
Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
JL Ethier, D Desautels, A Templeton, PS Shah, E Amir
Breast Cancer Research 19 (1), 1-13, 2017
4272017
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2014
3352014
Neutrophils in cancer: prognostic role and therapeutic strategies
A Ocana, C Nieto-Jiménez, A Pandiella, AJ Templeton
Molecular cancer 16 (1), 1-7, 2017
2572017
Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic
GS Kulkarni, T Hermanns, Y Wei, B Bhindi, R Satkunasivam, ...
Journal of clinical oncology 35 (20), 2299-2305, 2017
2252017
HER3 overexpression and survival in solid tumors: a meta-analysis
A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir
JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2013
1982013
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
I Cima, R Schiess, P Wild, M Kaelin, P Schüffler, V Lange, P Picotti, ...
Proceedings of the National Academy of Sciences 108 (8), 3342-3347, 2011
1972011
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of …
D Lorente, J Mateo, AJ Templeton, Z Zafeiriou, D Bianchini, ...
Annals of Oncology 26 (4), 750-755, 2015
1782015
Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ...
European urology 67 (4), 740-749, 2015
1702015
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis
A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ...
PloS one 9 (4), e95219, 2014
1552014
Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy
AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ...
European urology 70 (2), 358-364, 2016
1452016
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio
AJ Templeton, C Pezaro, A Omlin, MG McNamara, R Leibowitz‐Amit, ...
Cancer 120 (21), 3346-3352, 2014
1422014
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of …
AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ...
Annals of oncology 24 (12), 2972-2977, 2013
1342013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, ...
European urology 64 (1), 150-158, 2013
1332013
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two …
RJ Van Soest, AJ Templeton, FE Vera-Badillo, F Mercier, G Sonpavde, ...
Annals of Oncology 26 (4), 743-749, 2015
1322015
Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer
MG McNamara, AJ Templeton, M Maganti, T Walter, AM Horgan, ...
European Journal of Cancer 50 (9), 1581-1589, 2014
1182014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
C Rothermundt, S Hayoz, AJ Templeton, R Winterhalder, RT Strebel, ...
European urology 66 (3), 468-474, 2014
1152014
Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer
S Gillessen, A Templeton, G Marra, YF Kuo, E Valtorta, VB Shahinian
Journal of the National Cancer Institute 102 (23), 1760-1770, 2010
1142010
The system can't perform the operation now. Try again later.
Articles 1–20